Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer

LIBRETTO-531 is first ever Phase 3 trial in RET-mutant medullary thyroid cancer Randomized trial will examine selpercatinib against standard of care in 400 patients with advanced or metastatic treatment-naïve RET-mutant medullary thyroid cancer ... Biopharmaceuticals, Oncology Eli Lilly, selpercatinib, RET-mutant, medullary thyroid cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news